Non-alcoholic steatohepatitis

Intercept Implements Restructuring as Ocaliva’s Hopes for NASH Treatment Suffer Another FDA Rejection

Source – Intercept Ocaliva by Intercept wasn’t the fatty liver disease breakthrough that the company had anticipated it would be, ...